Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667-75: How Does Circulating DNA Reach the Blood Stream?
暂无分享，去创建一个
[1] M. Nykter,et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. , 2019, European urology.
[2] R. Montironi,et al. Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy , 2018, Cancers.
[3] A. Lopez‐Beltran,et al. Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy. , 2019, Current drug metabolism.
[4] A. Haese*,et al. Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer. , 2018, European urology.
[5] O. Sartor,et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA) , 2018, European urology.
[6] B. Tombal,et al. Cell-free DNA in Advanced Prostate Cancer: A Biomarker Revolution Under Way? , 2018, European urology.